Niclas Björn

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 10

Top Venues

NPJ precision oncology

Basic & clinical pharmacology & toxicology

The pharmacogenomics journal

NPJ systems biology and applications

Linköping University, Department of Biomedical and Clinical Sciences

Linköping University (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Linköping University, Department of Biomedical and Clinical Sciences

Sweden

Postdoctoral researcher :: Division of Drug Research

Linköping University, Department of Medical and Health Sciences

Sweden

PhD-student :: Division of Drug Research

Education History

Linköping University Aug 20 2009 - Jul 10 2014

Sweden

MSC

Publications

Kristina Engvall, Hanna Uvdal, Niclas Björn, Elisabeth Åvall-Lundqvist, Henrik Green
Prediction models of persistent taxane-induced peripheral neuropathy among breast cancer survivors using whole-exome sequencing. NPJ precision oncology 8 (1) (2024)
Kristina Engvall, Hanna Uvdal, Niclas Björn, Elisabeth Åvall-Lundqvist, Henrik Green
Prediction models of persistent taxane-induced peripheral neuropathy among breast cancer survivors using whole-exome sequencing. NPJ precision oncology 8 (1) (2024)
Kristina Engvall, Hanna Uvdal, Niclas Björn, Elisabeth Åvall-Lundqvist, Henrik Green
Prediction models of persistent taxane-induced peripheral neuropathy among breast cancer survivors using whole-exome sequencing. NPJ precision oncology 8 (1) (2024)
Ingrid Jakobsen Falk, Max Sundkvist, Niclas Björn, Henrik Green, Kourosh Lotfi
Early changes in gene expression profiles in AML patients during induction chemotherapy. BMC genomics 23 (1) (2022)
Niclas Björn, Ingrid Jakobsen Falk, Chihiro Udagawa, Eva Brandén, Hirsh Koyi, Rolf Lewensohn, Luigi De Petris, Hitoshi Zembutsu, Henrik Green
The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes. Basic & clinical pharmacology & toxicology 130 (4) (2022)
Niclas Björn, Tejaswi Venkata Satya Badam, Rapolas Spalinskas, Eva Brandén, Hirsch Koyi, Rolf Lewensohn, Luigi De Petris, Zelmina Lubovac-Pilav, Pelin Sahlén, Joakim Lundeberg, Mika Gustafsson, Henrik Gréen
Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients. NPJ systems biology and applications 6 (1) (2020)
Anna Åstrand, Svante Vikingsson, Ingrid Jakobsen Falk, Niclas Björn, Robert Kronstrand, Henrik Green
Activation of the μ-opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure. Drug testing and analysis 13 (1) (2020)
Niclas Björn, Ingrid Jakobsen Falk, Kourosh Lotfi, Henrik Green
Single-Cell RNA Sequencing of Hematopoietic Stem and Progenitor Cells Treated with Gemcitabine and Carboplatin. Genes 11 (5) (2020)
Niclas Björn, Benjamín Sigurgeirsson, Anna Svedberg, Sailendra Pradhananga, Eva Brandén, Hirsch Koyi, Rolf Lewensohn, Luigi de Petris, Maria Apellániz-Ruiz, Cristina Rodríguez-Antona, Joakim Lundeberg, Henrik Gréen
Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia. The pharmacogenomics journal 20 (2) (2019)
Niclas Björn, Ingrid Jakobsen Falk, Ignace Vergote, Henrik Green
ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients. Basic & clinical pharmacology & toxicology 123 (3) (2018)

Niclas Björn.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Niclas Björn